KVD001 Injection

DRUG2 trials

Sponsors

KalVista Pharmaceuticals, Ltd.

Conditions

Diabetic Macular Edema

Phase 1

A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME

CompletedNCT02193113

KalVista Pharmaceuticals, Ltd.Diabetic Macular Edema

Start: 2014-07-18End: 2015-06-04Updated: 2017-03-03

Phase 2

Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

CompletedNCT03466099

KalVista Pharmaceuticals, Ltd.Diabetic Macular Edema

Start: 2018-02-16End: 2019-10-10Updated: 2021-01-28

Related Papers

Bradykinin 1 Receptor Antagonist BI1026706 Does Not Reduce Central Retinal Thickness in Center-Involved Diabetic Macular Edema.

2020-03-306 citations